Paula  J. Hurley, Ph.D.
Paula J. Hurley, Ph.D.

Assistant Professor
Hinman Urologic Education Endowed Fund Scholar

Department of Urology And Oncology
Johns Hopkins University School of Medicine
Cancer Research Building II, Room 154 1550 Orleans Street Baltimore, MD 21287

Office: 410-614-9453


Fax: 410-502-9453


 Free access to abstracts at PubMed

Publications:  Peer-reviewed Original Science Research

  1. Boone DL, Lee EG, Libby S, Gibson PJ, Chien M, Chan F, Madonia M, Burkett PR, Ma A.  2002.  Recent advances in understanding NF-kappaB regulation.  Inflamm Bowel Dis.  May; 8(3):2001-12.
  2. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley PJ, Chien M, Chai S, Hitotsumatsu O, McNally E, Pickart C, and Ma A. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.   Nat Immunol 2004; (10): 1052-60.
  3. Topaloglu O, Hurley PJ, Yildirim O, Civin CI, Bunz F.  Improved methods for the generation of human gene knockout and knockin cell lines. Nucleic Acids Res 2005; (18): e158.
  4. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, and Hwang PM. p53 regulates mitochondrial respiration. Science 2006; (5780): 1650-3.
  5. Hurley PJ, Wilsker D, Bunz F.  2007.  Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation.  Oncogene.
  6. Hurley PJ, Bunz F. 2007.  ATM and ATR:  components of an integrated circuit.  Cell Cycle. Feb 15; 6(4):414-7.
  7. Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-Ross M.  2011.  Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity.  BJU Int. Aug; 108(3):447-54.
  8. Ross AE, Marchionni L, Phillips TM, Miller RM, Hurley PJ, Simons BW, Salmasi AH, Schaeffer AJ, Gearhart JP, Schaeffer EM.  2011. Molecular effects of genistein on male urethral development.  J Urol. May; 185(5):1894-8.
  9.  Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer EM.  2012.  Sox9 is required for prostate development and prostate cancer initiation.  Oncotarget. Jul; 3(6):651-63.
  10. Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe S, Miller RM, Erho NG, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, Berman DM, Schaeffer EM.  2012.  SPARCL1/Hevin is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.  PNAS. Sep 109(37):14977-82. 
  11. Simons B, Hurley PJ, Berman DM, Schaeffer, EM.  2012.  Wnt Signaling Through Beta-catenin is Required for Prostate Lineage Specification.  Dev Biol. Nov; 371(2):  246-55.
  12. Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J, Blair BG, Chu D, Burns T, Higgins M, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg D, Kessler J, Jeter S, Samuels ML, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH.  2014.  Detection of Cancer Specific Mutations in Plasma of Early Stage Breast Cancer Patients.  Clinical Cancer Research.

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion